


Claims

1. A compound of formula (I),




or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 for use as a pharmaceutical.
3. A compound for use according to claim 2 in the treatment of RSV infection and for the prevention of disease associated with RSV infection.
4. Use of a compound according to claim 1 for the manufacture of a medicament for the treatment of RSV infection and for the prevention or treatment of disease associated with RSV infection.
5. A compound for use or use according to either claim 3 or 4 wherein the RSV infection is infection by viruses of the RSV A strain and/or viruses of the RSV B strain.
6. The compound for use according to claim 2 as a pharmaceutical in combination with a second or further active ingredient.
7. A pharmaceutical composition comprising the compound according to claim 1 optionally in combination with one or more pharmaceutically acceptable diluents or carriers.
8. A pharmaceutical composition according to claim 7 comprising the compound of formula (I) in particulate form suspended in an aqueous medium.
9. A pharmaceutical composition according to claim 7 which comprises a second or further active ingredient.
10. A compound for use according to claim 6 or a pharmaceutical composition according to claim 9 wherein the second or further active ingredient is selected from anti-viral agents


(such as other anti-RSV agents) including F protein inhibitors (including anti-F-protein antibodies, such as palivizumab), RNA polymerase inhibitors and ribavirin and anti-inflammatory agents.

11. A process for the preparation of a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt thereof which comprises reacting a compound of formula (II)




or a salt thereof;
with 2-fluoro-6-methylaniline.

12. The compound of formula (II)




or a salt thereof.

13. A process for the preparation of a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt thereof which comprises reacting a compound of formula (III)




wherein LG is a halogen atom leaving group;
or a salt thereof;
with 7-oxa-2-azaspiro[3,5]nonane or a salt thereof.

14. A compound of formula (III)




wherein LG is a halogen atom leaving group;
or a salt thereof.

15. A process for the preparation of a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt thereof which comprises reacting a compound of formula (IV)




or a salt thereof;
with the compound of formula (VI).




or a salt thereof.

16. A compound of formula (IV)




or a salt thereof.

17. A compound of formula (VI)




or a salt thereof.

18. A process for the preparation of the compound of formula (II) or a salt thereof which comprises reacting a compound of formula (X)



wherein LG is a halogen atom leaving group, and R^a is C₁₋₆ alkyl;
or a salt thereof;
with 7-oxa-2-azaspiro[3,5]nonane or a salt thereof, followed by hydrolysis of the
carboxylate ester to the free acid.

19. A compound of formula (X)



wherein LG is a halogen atom leaving group, and R^a is C₁₋₆ alkyl;
or a salt thereof.